ESRD from lupus nephritis in the United States, 1995–2010

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 2, 2015, Pages 251-259

  Sexton, Donal J ^a,b   Reule, Scott ^a,b   Solid, Craig ^a   Chen, Shu Cheng ^a   Collins, Allan J ^a,b   Foley, Robert N ^a,b  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ALBUMIN BLOOD LEVEL; ALCOHOL ABUSE; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABUSE; END STAGE RENAL DISEASE; ETHNICITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PERIPHERAL VASCULAR DISEASE; RETROSPECTIVE STUDY; SMOKING; UNITED STATES; DISEASE COURSE; EPIDEMIOLOGY; ETHNOLOGY; HEALTH CARE DISPARITY; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; PROGNOSIS; RENAL REPLACEMENT THERAPY; RISK FACTOR; TIME FACTOR; YOUNG ADULT;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; HEALTHCARE DISPARITIES; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROGNOSIS; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84923791562     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02350314     Document Type: Article

References (33)

1. Mok CC, Kwok RC, Yip PS: Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 65: 2154–2160, 2013.
2. Cameron JS: Lupus nephritis. J Am Soc Nephrol 10: 413–424, 1999.
3. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314: 614–619, 1986.
4. Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741–745, 1992.
5. Levey AS, Lan SP, Corwin HL, Kasinath BS, Lachin J, Neilson EG, Hunsicker LG, Lewis EJ: Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 116: 114–123, 1992.
6. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed ER, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46: 2121–2131, 2002.
7. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN; Hong Kong-Guangzhou Nephrology Study Group: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl JMed 343: 1156–1162, 2000.
8. Houssiau FA, D’Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, de Ramon Garrido E, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R; MAINTAIN Nephritis Trial Group: Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 69: 2083–2089, 2010.
9. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353: 2219–2228, 2005.
10. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, Assmann KJ, Bruijn JA, Weening JJ, van Houwelingen HC, Derksen RH, Berden JH; Dutch Working Party on Systemic Lupus Erythematosus: Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 70: 732–742, 2006.
11. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, Roth D: Sequential therapies for proliferative lupus nephritis. N Engl J Med 350: 971–980, 2004.
12. Austin HA 3rd, Illei GG, Braun MJ, Balow JE: Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 20: 901–911, 2009.
13. Favas C, Isenberg DA: B-cell-depletion therapy in SLE—what are the current prospects for its acceptance? Nat Rev Rheumatol 5: 711–716, 2009.
14. Costenbader KH, Desai A, Alarcón GS, Hiraki LT, Shaykevich T, Brookhart MA, Massarotti E, Lu B, Solomon DH, Winkelmayer WC: Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 63: 1681–1688, 2011.
15. U.S. Department of Commerce: U.S. Census Bureau. 2013. Available at: http://www.census.gov/. Accessed October 14, 2014.
16. U.S. Department of Health and Human Services, Centers for Medicare &Medicaid Services: End Stage Renal Disease Medical Evidence Report Medicare Entitlement and/or Patient Registration: Form CMS-2728-U3.. 2006. Available at: http://www.cms.gov/Medicare/CMS-Forms/CMS-Forms/downloads/cms2728. pdf. Accessed October 14, 2014.
17. Centers for Disease Control and Prevention: Hispanic or Latino populations. 2014. Available at: http://www.cdc.gov/minorityhealth/populations/REMP/hispanic.html. Accessed October 14, 2014.
18. Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K, Nahar N, de La Cuesta C, Hurtado A, Fornoni A, Beltran-Garcia L, Asif A, Young L, Diego J, Zachariah M, Smith-Norwood B: Outcomes in AfricanAmericans andHispanicswith lupus nephritis. Kidney Int 69: 1846–1851, 2006.
19. Somers EC, Marder W, Cagnoli P, Lewis EE, DeGuire P, Gordon C, Helmick CG, Wang L, Wing JJ, Dhar JP, Leisen J, Shaltis D, McCune WJ: Population-based incidence and prevalence of systemic lupus erythematosus: The Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheum (Munch) 66: 369–378, 2014.
20. Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, Birmingham DJ, Hebert LA, Hicks PJ, Segal MS, Edberg JC, Brown EE, Alarcón GS, Costenbader KH, Comeau ME, Criswell LA, Harley JB, James JA, Kamen DL, Lim SS, Merrill JT, Sivils KL, Niewold TB, Patel NM, Petri M, Ramsey-Goldman R, Reveille JD, Salmon JE, Tsao BP, Gibson KL, Byers JR, Vinnikova AK, Lea JP, Julian BA, Kimberly RP; Lupus Nephritis–End-Stage Renal Disease Consortium: End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheum (Munch) 66: 390–396, 2014.
21. Devlin A, Waikar SS, Solomon DH, Lu B, Shaykevich T, Alarcón GS, Winkelmayer WC, Costenbader KH: Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United States. Arthritis Care Res (Hoboken) 63: 1642–1653, 2011.
22. Nee R, Jindal RM, Little D, Ramsey-Goldman R, Agodoa L, Hurst FP, Abbott KC: Racial differences and income disparities are associatedwith poor outcomes in kidney transplant recipients with lupus nephritis. Transplantation 95: 1471–1478, 2013.
23. Hiraki LT, Lu B, Alexander SR, Shaykevich T, Alarcón GS, Solomon DH, Winkelmayer WC, Costenbader KH: End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. Arthritis Rheum 63: 1988–1997, 2011.
24. Van Bruggen MC, Walgreen B, Rijke TP, Berden JH: Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 9: 1407–1415, 1998.
25. Glicklich D, Acharya A:Mycophenolatemofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 32: 318–322, 1998.
26. Hogan J, Schwenk MH, Radhakrishnan J: Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis? Kidney Int 82: 1256–1260, 2012.
27. Morris HK, Canetta PA, Appel GB: Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis. Nephrol Dial Transplant 28: 1371–1376, 2013.
28. Appel GB: New and future therapies for lupus nephritis. Cleve Clin J Med 79: 134–140, 2012.
29. Fu LW, Yang LY, Chen WP, Lin CY: Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Rheumatol 37: 217–221, 1998.
30. Bartels CM, Ramsey-Goldman R: Editorial: Updates in US systemic lupus erythematosus epidemiology: Tales of two cities. Arthritis Rheum (Munch) 66: 242–245, 2014.
31. Lim SS, Bayakly AR, Helmick CG, Gordon C, Easley KA, Drenkard C: The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry. Arthritis Rheum (Munch) 66: 357–368, 2014.
32. McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK: Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 38: 1260–1270, 1995.
33. Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R, D’Cruz DP: Rituximab in the treatment of resistant lupus nephritis: Therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 22: 574–582, 2013.